Katherine Harris, PhD

Vice President, Discovery at Amgen

Dr. Katherine Harris is currently the Vice President of Discovery at Teneobio, a multi-specific biotherapeutic antibody company redirecting the immune system to fight cancer. She joined Teneobio when the company started lab operations in 2015, playing a key role in both building and managing a high-throughput antibody discovery platform. Prior to her work at Teneobio, she was a research scientist at Active Motif and SwitchGear Genomics where she focused her efforts on developing a functional genomics platform for small molecule screening. Katherine holds a Ph.D. in Molecular and Cell Biology from the University of California, Berkeley.